TMS for Anxiety: What the Research Shows in 2026
At a Glance
- TMS (transcranial magnetic stimulation) uses magnetic pulses to modulate neural activity in targeted brain regions. For anxiety, the right dorsolateral prefrontal cortex (DLPFC) is the primary target, using inhibitory low-frequency protocols.
- TMS is FDA-cleared for major depressive disorder (2008) and OCD (2018), but not specifically for generalized anxiety disorder. Anxiety symptoms frequently improve as a secondary outcome in depression TMS trials.
- A 2023 meta-analysis of 14 RCTs found significant anxiety symptom reduction following TMS, with effect sizes comparable to first-line medications.
- The Stanford SAINT protocol (intensive TMS for depression) has shown rapid anxiety co-morbidity improvement in initial studies, but is not yet standard of care for anxiety.
- A typical course is 36 sessions over 6 to 9 weeks at $200 to $400 per session. Accelerated protocols can compress this to 5 days but are not widely available.
TMS has a clear FDA-cleared indication for treatment-resistant depression, and a growing body of evidence for OCD. Its application to anxiety disorders sits in an interesting middle ground: not yet FDA-cleared specifically for anxiety, but with meaningful clinical trial data and a plausible neurobiological rationale that has driven widespread off-label clinical use.
For patients with anxiety disorders who have not responded adequately to medication or therapy, TMS represents a legitimate option worth understanding in detail. This article covers the mechanism, the clinical evidence, the current regulatory status, and practical considerations for patients evaluating TMS.
How TMS Works for Anxiety
TMS devices generate brief, intense magnetic field pulses that penetrate the skull and induce small electrical currents in the underlying cortex. Depending on the frequency and pattern of the pulses, TMS can either increase (excite) or decrease (inhibit) neural activity in the targeted region. This is not a generalized brain stimulation: the effects are spatially localized to a few centimeters of cortex directly beneath the coil.
For depression, the standard target is the left DLPFC, stimulated at high frequency (10 Hz or intermittent theta burst) to increase activity in an area that is typically underactive in depressed patients. For anxiety, the targeting logic is somewhat different and more varied across clinical protocols.
The DLPFC and Anxiety: Right vs. Left
The DLPFC plays a key role in top-down regulation of emotional responses. It modulates activity in the amygdala and other limbic structures involved in the fear response. In anxiety disorders, there is evidence of hyperactivity in right-hemisphere frontal regions and relative underactivity in the left hemisphere, a pattern roughly opposite to what is seen in depression.
Based on this asymmetry, TMS protocols for anxiety typically use one of three approaches: low-frequency (1 Hz) stimulation of the right DLPFC to inhibit overactive right frontal circuitry; high-frequency (10 Hz) stimulation of the left DLPFC to increase regulatory activity (the same target used in depression); or continuous theta burst stimulation (cTBS) of the right DLPFC for a faster inhibitory effect. The right-sided inhibitory approach has the strongest mechanistic rationale specifically for anxiety, though the depression literature (which uses left-sided excitatory stimulation) contains substantial anxiety comorbidity data.
Deep TMS and the Medial Prefrontal Cortex
Deep TMS (dTMS), which uses the H-coil to reach deeper cortical and subcortical structures, can also target the medial prefrontal cortex (mPFC) and anterior cingulate cortex, regions directly involved in anxiety regulation. The FDA-cleared OCD protocol uses dTMS targeting the mPFC and anterior cingulate. Several ongoing trials are evaluating dTMS for generalized anxiety disorder (GAD) specifically, with the SAINT-like intensive protocols showing particular promise.
FDA Clearance Status: What Is and Is Not Approved
Understanding the FDA clearance picture for TMS requires distinguishing between device clearances and indication clearances.
TMS is FDA-cleared for: major depressive disorder (MDD) in adults who have failed one antidepressant trial (cleared 2008, multiple subsequent device clearances); obsessive-compulsive disorder using dTMS with the Brainsway H7 coil (cleared 2018); and adjunctive treatment of MDD using dTMS (cleared 2013). TMS is not specifically FDA-cleared for: generalized anxiety disorder, social anxiety disorder, PTSD, panic disorder, or specific phobia. However, TMS is legally used off-label for these conditions, and the clinical evidence for anxiety specifically is meaningful enough that many psychiatrists and TMS practices offer it as a primary treatment.
A few points about OCD clearance: OCD has significant anxiety features, and the FDA-cleared dTMS protocol targets brain regions (mPFC, anterior cingulate) that are also implicated in anxiety disorders. The OCD clearance does not extend to GAD or other anxiety conditions, but it demonstrates that magnetic stimulation of relevant circuits can modulate pathological anxiety.
Clinical Trial Evidence for Anxiety
Generalized Anxiety Disorder
The evidence base for TMS in GAD is growing but not yet at the level of depression. A 2020 RCT by Dilkov et al. in Psychiatry Research (n=40) used 1 Hz right DLPFC TMS for 20 sessions versus sham. The TMS group showed a 60% reduction in Hamilton Anxiety Scale (HAM-A) scores versus 27% in the sham group, with effects maintained at 3 months. This is one of the best-designed GAD-specific TMS trials published.
A 2023 meta-analysis by Deng et al. in the Journal of Psychiatric Research analyzed 14 RCTs (combined n=724) that included anxiety outcomes, including studies where anxiety was a primary or secondary endpoint. TMS produced a standardized mean difference of 0.68 in anxiety symptom reduction versus sham, which is a medium-to-large effect size and comparable to the response seen with first-line pharmacotherapy. Evidence grade: Moderate.
Anxiety as a Depression Comorbidity
The largest body of data on TMS and anxiety comes from depression trials where anxiety symptoms were measured as secondary outcomes. The large multisite NeuroStar TMS clinical trial (O’Reardon et al., 2007, Biological Psychiatry, n=301) measured anxiety symptoms using the HAM-A and found significant improvement in anxious features in the TMS group. A 2017 naturalistic study of 307 patients receiving TMS for depression at multiple centers found that 56% of patients with clinically significant baseline anxiety achieved remission of anxiety symptoms by end of treatment.
PTSD: Emerging Evidence
PTSD represents one of the most active research areas for TMS outside of depression. A 2020 RCT by Petrosino et al. in the Journal of Affective Disorders (n=65) using bilateral DLPFC TMS found a 40% reduction in PTSD Checklist scores versus 14% in the sham group after 20 sessions. The VA and Department of Defense have funded several ongoing trials examining TMS as a treatment for combat-related PTSD. Evidence grade: Emerging.
The Stanford SAINT Protocol and Accelerated TMS
The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol gained significant attention after a 2021 study in the American Journal of Psychiatry (Cole et al., n=29) showed a 78.6% remission rate in treatment-resistant depression after just 5 days of intensive TMS. This compares to remission rates of 30% to 50% with standard TMS over 6 weeks. SAINT uses individualized targeting based on fMRI connectivity mapping, higher intensity stimulation, and 10 sessions per day for 5 days (versus 1 session per day for 36 days in standard protocols).
The SAINT study did not specifically target anxiety, but participants with comorbid anxiety showed improvement alongside depression. A follow-up study and replication at other sites are ongoing. SAINT received FDA Breakthrough Device designation and a 510(k) clearance (for MDD) in 2022. It is not yet widely available and costs considerably more than standard TMS. For anxiety specifically, SAINT-like accelerated protocols are being studied but are not yet standard of care.
TMS vs. Medication for Anxiety: A Comparison
| Factor | TMS | SSRI/SNRI Medications | Benzodiazepines |
|---|---|---|---|
| Mechanism | Modulates prefrontal cortex activity and limbic regulation | Increases serotonin or norepinephrine availability | GABA receptor enhancement, rapid anxiolysis |
| Onset of effect | Gradual over 2 to 4 weeks, some sooner | 2 to 6 weeks for full effect | Minutes to hours |
| Duration of benefit | 6 to 12+ months in responders | Maintained while taking; variable after stopping | Hours; no lasting benefit with regular use |
| Systemic side effects | None (localized headache is most common) | Sexual dysfunction, weight changes, GI upset, fatigue | Sedation, cognitive impairment, dependence risk |
| Addiction potential | None | None | High with regular use |
| FDA status for anxiety | Not cleared for anxiety specifically | Multiple approved for GAD, panic, social anxiety, PTSD | Approved short-term; not recommended long-term |
| Cost | $200 to $400 per session, 36 sessions standard | $10 to $200 per month depending on medication | $15 to $50 per month |
| Insurance coverage | Variable; better for depression comorbidity | Usually covered | Usually covered |
TMS is not a first-line treatment for anxiety. The standard approach is cognitive behavioral therapy (CBT), which has the strongest evidence base across anxiety disorders, often combined with an SSRI or SNRI. TMS becomes relevant for patients who have not responded adequately to these first-line approaches, who cannot tolerate medication side effects, or who have significant depression comorbidity alongside their anxiety.
What a TMS Course Looks Like: Practical Details
Standard TMS for anxiety follows a similar structure to depression protocols. A typical course involves:
- Initial psychiatric evaluation to confirm diagnosis, rule out contraindications, and determine targeting approach
- Motor threshold assessment (a brief calibration procedure to set the stimulation intensity for each individual)
- 36 sessions of 20 to 37 minutes each, delivered Monday through Friday over 6 to 9 weeks
- Each session involves sitting in a chair with the TMS coil placed against the head; patients are awake and can talk during treatment
- Mild scalp discomfort or headache during or after treatment is the most common side effect, typically managed with acetaminophen
- Booster sessions may be offered if symptoms return after an initial response
Contraindications include metal implants in or near the head (cochlear implants, aneurysm clips, metal skull plates), history of seizures, and certain cardiac devices. TMS is generally safe in patients with metal dental work or braces, as these are outside the field range of the coil.
Insurance Coverage and Cost Realities
Insurance coverage for TMS is most reliable when the primary diagnosis is major depressive disorder and there is documented failure of at least one antidepressant. For anxiety as a primary indication, coverage is inconsistent and often requires appeals. Many practices offer TMS for anxiety under a depression comorbidity framework if that diagnosis is present, which is common given how frequently depression and anxiety co-occur.
Out-of-pocket costs for a full 36-session course run $7,200 to $14,400 at $200 to $400 per session. Some practices offer sliding scale fees or payment plans. The cost comparison that matters for treatment-resistant patients is not TMS versus generic SSRIs, but TMS versus ongoing medication management, psychiatric visits, and the indirect costs of inadequately treated anxiety over months or years.
The Bottom Line
TMS is a legitimate, evidence-supported treatment option for anxiety, particularly for patients with treatment-resistant GAD, PTSD, or anxiety comorbid with depression. The evidence is not as strong or as extensively replicated as it is for MDD, and the lack of a specific FDA clearance for anxiety means insurance coverage is harder to obtain. But the clinical trial data is consistent enough, and the safety profile favorable enough, that off-label use in appropriate patients is well-justified.
If you are considering TMS for anxiety, the most important step is finding a TMS provider with psychiatric expertise who can evaluate whether your anxiety subtype and history make you a good candidate, and who will specify which targeting protocol they use and why. The neurobiological rationale for TMS in anxiety is solid. The translation to your specific situation requires clinical judgment that no article can substitute for.
